Positive high-level results of COMET Phase III trial of oral Koselugo (selumetinib) in adults with neurofibromatosis type 1 – AstraZeneca
Positive high-level results of KOMET, the largest, global randomised double-blind placebo-controlled multicentre Phase III trial in adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas… read more.
